← Leaderboards
Sanjiv Agarwala
University Of Pittsburgh At Pittsburgh
$18,204
Attributed
$18,204
Total exposure
6
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$18,204 · 6
By mechanism
M01$18,204 · 6
Top collaborators
No co-investigators on record.
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Surinder Kumar Batra$34,830,369
- Donald L Trump$24,661,732
- Jeremy N Rich$24,023,429
- Jennifer R Grandis$109,711,044
- Michael T Lotze$5,139,928
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectHuman Therapy EvaluationClinical ResearchNeoplasm /Cancer ChemotherapyHead /Neck NeoplasmMetastasisMelanomaClinical Trial Phase IAntineoplasticsGene ExpressionHormone TherapyPolymerase Chain ReactionSquamous Cell CarcinomaBrain NeoplasmsTumor Suppressor GenesRecombinant ProteinsSuraminTemozolomideXerostomiasCerebrospinal FluidDosageDrug Administration Rate /DurationDrug Adverse EffectDrug Screening /Evaluation
Grant awards (12)
PHASE II STUDY OF TEMOZOLOMIDE (SCH52365) PRIOR TO RADIATION THERAPY$0
M01 · FY2002 · RR
PHASE I STUDY OF RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF HEAD/NECK$0
M01 · FY2002 · RR
PHASE I STUDY OF RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF HEAD/NECK$0
M01 · FY2002 · RR
PHASE II STUDY OF TEMOZOLOMIDE (SCH52365) PRIOR TO RADIATION THERAPY$0
M01 · FY2002 · RR
PHASE II STUDY OF TEMOZOLOMIDE (SCH52365) PRIOR TO RADIATION THERAPY$0
M01 · FY2001 · RR
PHASE I STUDY OF RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF HEAD/NECK$0
M01 · FY2001 · RR
PHASE II STUDY OF TEMOZOLOMIDE (SCH52365) PRIOR TO RADIATION THERAPY$3,034
M01 · FY2000 · RR
PHASE I STUDY OF RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF HEAD/NECK$3,034
M01 · FY2000 · RR
TEMOZOLOMIDE IN TREATMENT OF METASTATIC MELANOMA W/ BRAIN METASTASES$3,034
M01 · FY2000 · RR
OPEN LABEL RANDOMIZED STUDY TO EVAL EFFECT SAFETY OF 2 TREATMENTS$3,034
M01 · FY2000 · RR
PHASE II STUDY OF SURAMIN IN PATIENTS WITH METASTATIC MELANOMA$3,034
M01 · FY2000 · RR
RECOMBINANT KERATINOCYTE GROWTH FACTOR FOR HEAD &NECK CANCER$3,034
M01 · FY2000 · RR